Mourabit Halima, Author at MediaMedic

ASH 2024 | Dr. Mingfeng Zhao: Pursuing Innovation—iCAR-T Therapy Offers New Hope for AML Treatment

By Mourabit Halima 2024.12.26

Acute myeloid leukemia (AML) remains a major clinical challenge due to its high heterogeneity. While CAR-T cell therapy has shown tremendous success in treating various hematologic malignancies, its application in AML is still in its infancy, necessitating further research and exploration. At the 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7–10, Dr. Mingfeng Zhao from Tianjin First Central Hospital presented groundbreaking findings on a novel iCAR-T therapy for AML, offering renewed hope for patients. Hematology Frontier had the privilege of inviting Prof. Zhao to discuss this study and share insights on his team’s future research plans.

ASH 2024 | Dr. Wenbin Qian: In-Depth Analysis of Three Key Advances in CAR-T Cell Therapy for Lymphoma

By Mourabit Halima 2024.12.26

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, bringing together global experts and scholars in hematology for an in-depth exploration and exchange of the latest research progress in the field. Among the highlights of this year’s conference were three oral presentations (Oral 94, 238, 367) focusing on CAR-T cell therapy for lymphoma. These studies showcased the latest advancements in CAR-T therapy from three perspectives: enhancing accessibility, optimizing efficacy, and addressing resistance mechanisms. Hematology Frontier invited Dr. Wenbin Qian from The Second Affiliated Hospital of Zhejiang University School of Medicine to provide an in-depth analysis of these three studies, offering valuable guidance and insights for clinical practice.

ASH 2024 | Dr. Peihua Lu: Promising Efficacy and Controllable Safety of CD7 CAR-T Cell Therapy in Treating R/R PTCL

By Mourabit Halima 2024.12.26

The 66th American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10, 2024, in San Diego, showcased cutting-edge advancements in hematology. Among the highlights was a study led by Dr. Peihua Lu from the Beijing Lu Daopei Hematology Hospital, presenting Phase I clinical trial results on CD7 CAR-T cell therapy for relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). In this feature, Hematology Frontier invited Professor Lu to share insights into the study's findings, the strategy for expanding CD7 CAR-T indications, and future research plans.

ASH 2024 | Dr. Sizhou Feng: Improved Preconditioning Regimens and Novel Maintenance Therapies Bring New Momentum to Leukemia Transplantation

By Mourabit Halima 2024.12.26

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, bringing together global experts and scholars in hematology for an in-depth exploration and exchange of the latest research progress in the field. At this conference, two studies by Dr. Sizhou Feng's team from the Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences) were included for poster presentation (P2127, P2828). "Hematology Frontier" specially invited Dr. Feng to share the research findings and their clinical significance with colleagues at the ASH venue as soon as possible.

$ASH 2024 | Dr. Qingqing Cai on Innovations in Immunotherapy for Relapsed/Refractory Lymphoma$

ASH 2024 | Dr. Qingqing Cai on Innovations in Immunotherapy for Relapsed/Refractory Lymphoma

By Mourabit Halima 2024.12.25

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, USA, bringing together global experts and scholars in hematology to discuss the latest research developments. At this year’s conference, Dr. Qingqing Cai’s team from Sun Yat-sen University Cancer Center presented two research posters (P3047, P4450), offering novel perspectives and important insights into immunotherapy combinations for relapsed/refractory lymphoma. Hematology Frontier invited Dr. Cai to share the clinical significance and key findings of her team’s research.

ASH 2024 | Dr. Wei Xu: Redefining CNS Involvement Evaluation and Prophylactic Strategies with CSF-ctDNA Testing

By Mourabit Halima 2024.12.25

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, bringing together global experts and scholars to discuss cutting-edge advancements in hematology. At this prestigious event, Dr. Wei Xu’s team from The First Affiliated Hospital of Nanjing Medical University presented their groundbreaking research titled Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort. This study, selected for oral presentation (O576), not only deepens our understanding of CNS involvement in DLBCL but also offers innovative perspectives for clinical management and treatment strategies. Hematology Frontier invited Dr. Xu to share insights into the significance of CSF-ctDNA testing, its potential role in future DLBCL clinical practice, and its far-reaching impact on patient treatment strategies.

ASH 2024 | Dr. Haiwen Huang: Insights into New Strategies for Non-Hodgkin Lymphoma (NHL)—CMOP±R Regimen, Combined Therapies, and Transplant Options

By Mourabit Halima 2024.12.25

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) took place in San Diego, USA, gathering leading global experts to discuss the latest advancements in hematology. At this year’s conference, Dr. Haiwen Huang’s team from The First Affiliated Hospital of Soochow University presented three impactful studies through poster sessions (P1676, P3113, P4442). Hematology Frontier invited Professor Huang to share their insights and the clinical implications of these studies directly from the ASH venue.

SABCS 2024 | Dr. Biyun Wang: Real-World Comparison of CDK4/6 Inhibitor + Endocrine Therapy vs. Chemotherapy for First-Line HR+/HER2- MBC Treatment

By Mourabit Halima 2024.12.25

In the treatment landscape of HR+/HER2- metastatic breast cancer (MBC), CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) have become a widely used first-line treatment. However, patients with symptomatic visceral metastases often opt for chemotherapy (CT). While some prospective studies suggest that CDK4/6i + ET may yield better outcomes even in patients with visceral metastases, no studies have explored these strategies in real-world settings.

SABCS 2024 | Dr. Biyun Wang: Latest Clinical Trial Results of GQ1005 in HER2-Positive Metastatic Breast Cancer Patients

By Mourabit Halima 2024.12.24

The 47th San Antonio Breast Cancer Symposium (SABCS) is in full swing in San Antonio, USA, showcasing cutting-edge research from around the world. On December 12 (Central Time), during the “Poster Spotlight – Session 8: Novel HER2 Therapeutics”, Dr. Biyun Wang and her team from Fudan University Shanghai Cancer Center presented their groundbreaking findings on GQ1005, a highly promising HER2 antibody-drug conjugate (ADC). The study’s evaluation of GQ1005’s efficacy and safety in HER2-positive metastatic breast cancer (MBC) patients drew significant attention, leading to vibrant discussions among experts. Dr. Wang provides an in-depth interpretation of this important research.

Dr. Yunjian Liu: The Emerging Value of ctDNA Monitoring in Neoadjuvant Therapy for Breast Cancer—Predicting Treatment Response and Recurrence Risk

By Mourabit Halima 2024.12.24

From December 10 to 13, 2024, the 47th San Antonio Breast Cancer Symposium (SABCS) took place in San Antonio, USA. As one of the largest and most prestigious scientific gatherings in the field of breast cancer research, SABCS showcased the latest findings, clinical practices, treatment advancements, and technological innovations from the past year.Among the many noteworthy contributions, a study by Dr. Yunjian Liu's team from The Fourth Hospital of Hebei Medical University stood out. Their research focused on the prognostic value of ctDNA monitoring in breast cancer patients undergoing neoadjuvant therapy and was presented as a poster (Abstract No. P3-05-22). The study highlights how personalized ctDNA testing can dynamically monitor minimal residual disease (MRD), predict treatment efficacy and recurrence risk, and provide valuable insights for clinical decision-making. Oncology Frontier interviewed Professor Liu onsite for an in-depth discussion.